Literature DB >> 232662

[Pharmacologic effects of the antihypertensive 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazine (BQ 22-708, endralazine)].

R Salzmann, H Bürki, D Chu, B Clark, P Marbach, R Markstein, H Reinert, H Siegl, R Waite.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 232662

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN： 0004-4172


× No keyword cloud information.
  6 in total

1.  Changes in renal function induced by endralazine, a new antihypertensive drug.

Authors:  E Wegmüller; F C Reubi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.

Authors:  P A Reece; I Cozamanis; R Zacest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.

Authors:  W A Bogers; L Meems
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.

Authors:  J Kindler; P C Rüegg; M Neuray; W Pacha
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Effects of intravenous endralazine in essential hypertension.

Authors:  J J Hoffmann; T Thien; A van T'Laar
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

6.  Evaluation of once daily endralazine in hypertension.

Authors:  R Wu; J D Spence; S G Carruthers
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.